To evaluate in vitro glucocorticoid responsiveness of phytohemagglutinin (PHA)-stimulated lymphocytes from peritoneal dialysis (PO) patients compared to hemodialysis (HO) patients.
Design
Cross-sectional study of prevalent PO and HO patients and concurrent control subjects.
Setting
Urban outpatient dialysis unit.
Patients
20 HO, 14 PO, and 20 control subjects.
Measurements
Using standard lymphocyte culture techniques, the concentration of prednisolone (P) and methylprednisolone (MP) required to cause 50% inhibition (ICso) of the proliferative response to phytohemagglutinin (PHA) was determined from dose-response curves.
Results
There was considerable heterogeneity in the sensitivities of individual patients’ PBMC to glucocorticoid inhibition, especially those of HO patients’ cells to P. The mean: i: SO ICso for MP was significantly (p ≤ 0.001) lower than that for P in each cohort: PO 11 ± 5 vs. 34 ± 18 ng/mL; HO 22 ± 14 vs. 89 ± 43 ng/mL; control subjects 14 ± 11 vs. 55 ± 56 ng/mL. Interestingly, the ICSO for both P and MP was significantly higher in HO than in either PO or controls (ANOVA, P: F = 6.56, p = 0.003; MP: F = 3.77, p = 0.03), indicating decreased sensitivity of HO lymphocytes to both drugs. There were no significant differences in mean ICSO values for either P or MP between PO and controls. No correlations were found between ICSO for either P or MP and patient age, gender, duration of dialysis, serum creatinine, serum albumin, or parathyroid hormone level.
Conclusions
In vitro glucocorticoid responsiveness of dialysis patients’ lymphocytes appears to be influenced by dialysis modality, butthefactor(s) involved remains to be determined. Thegreater sensitivity of PO lymphocytes to both P and MP might result in better immunosuppression and less severe rejection after renal transplantation. MP may be particularly advantageous following renal transplantation for any patient manifesting relative or absolute in vitro resistance to P.
PoznanskyM.C., GordonA.C.H., DouglasJ.G., KrajeewskiA.S., WyllieA.H., GrantI.W.B.Resistance to methylprednisolone in cultures of blood mononuclear cells from glucocorticoid-resistant asthmatic patients.Clin Sci (London)1984; 67: 639–45.
2.
WilkinsonJ.R.W., CreaA.E.G., ClarkT J.H., LeeT.H.Identification and characterization of a monocyte-derived neutrophil-activating factor in corticosteroid-resistant bronchial asthma.J Clin Invest1989; 84: 1930–41.
3.
KirkamB.W., CorkillM.M., DavisonS.C., PanayiG.S.Response to glucocorticoid treatment in rheumatoid arthritis: in vitro mediated immune assay predicts in vivo responses.J Rheumatol1991; 18: 821–5.
4.
ChikanzaI.C., PanayiG.S.The effects of hydrocortisone on in vitro lymphocyte proliferation and interleukin-2 and -4 production in corticosteroid sensitive and resistant subjects.Eur J Clin Invest1993; 23: 845–50.
5.
KraftN., AtkinsR.C., Thomson. Differential susceptibility in vitro to methylprednisolone of human lymphocyte subpopulations stimulated by phytohemagglutinin.Transplant Proc1979; 11: 1375–6.
6.
WalkerK.B., PotteerJ.M., HouseA.K.Variable inhibition of mitogen induced blastogenesis in humanlymphocyte bypred nisolone in vitro.TransplantProc1985; 17: 1676–8.
7.
HouseA.K., PotterJ.M., WalkerK.B.Prednisolone and rejection: suppressed lymphocyte blastogenesis and allograft rejection.Transplant Proc1986; 18: 211–4.
8.
LanghoffE.Jakobsen BK, Ryder LP, Ladefoged J, Platz P, Svejgaard A, Thayson JH. Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival.Lancet1986; 1: 1286–97.
9.
LanghoffE., LadefogedJ.The impact of highlymphocyte sensitivity to glucocorticoids on kidney graft survival in patients treated with azathioprine and cyclosporine.Transplantation1987; 43: 380–4.
10.
FrancisD.M.A., DumbleL.T., BowesL., ClunieG.J.A., MacDonaldI.M.Adverse influence of recipient lymphoid resistance to in vitro immunosuppression on the outcome of kidney transplants.Transplantation1988; 46: 853–7.
11.
Pollak, DumbleL.J., LazdaV.A., MadduxM.S., StormoenB., WardM.Utility of an in vitro immunoassay to guide immunosuppressive therapy.Transplant Proc1991; 23: 1113–4.
12.
KangX-X, HiranoT., OkaK., SakuraiE., TamakiT., KozakiM.Role of altered prednisolone-specific lymphocyte sensitivity in chronic renal failure as a pharmacodynamic marker of acute allograft rejection after kidney transplantation.Eur J Clin Pharmacol1991; 41: 417–23.
13.
HiranoT., OkaK., TakeuchiH.Clinical significance of glucocorticoid pharmacodynamics assessed by anti-lymphocyte action in kidney transplantation. Marked difference between prednisolone and methylprednisolone.Transplantation1994; 57: 1341–8.
JuskoW.J.Corticosteroid pharmacodynamics: models for a broad array of receptor-mediated pharmacologic effects.J Clin Pharmacol1990; 30: 303–10.
16.
LanghoffE., HvidbeergE.F., FlachsH., LadefogedJ.Glucocorticoid levels and lymphocyte functions in kidney transplanted patients.Pharmacol Toxicol1987; 60: 269–73.
17.
OstL., BjorkhemI., von BahrC.Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation.Eur J Clin Pharmacol1984; 133: 363–9.
18.
FreyB.M., FreyW.F.J., de Weck. Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function.J Immunol1984; 133: 2479–87.
19.
TornatoreK.M., ReedK., WalsheJ.J., VenutoR.C.Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients.Pharmacotherapy1984; 14: 111–8.
20.
TornatoreK.M., ReedK.A., VenutoR.C.Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients.Ann Pharmacother1995; 29: 120–4.
21.
TornatoreK.M., BiocevichD.M., ReedK., TousleyK., SinghJ.P., VenutoR.C.Methylprednisolone pharmacokinetics, cortisol response and adverse effects in black and white renal transplant recipients.Transplantation1985; 59: 729–36.
22.
WalkerK.B., PotterJ.M., HouseA.K.Interleukin2 synthesis in the presence of steroids: a model of steroid resistance.Clin Exp Immunol1987; 68: 162–7.
LugerA., KovarikJ., StummvollH.K., UrbanskaA., LugerT.Blood-membrane interaction in hemodialysis leads to increasedcytokine productionKidney Int1987; 32: 84–8.
25.
LonnemannG., VanDeer MeerJ.W.M., CannonJ.G.Induction of tumor necrosis factor during extracorporeal blood purification.N Engl J Med1987; 317: 963–4.
26.
ShaldonS., KochK.M., DinarelloC.A.Interleukin-l activation and acute phase response during hemodialysis.Contrib Nephrol1988; 61: 18–26.
27.
KimmelP.L., PhillipsT.M., PhillipsE., BoschJ.P.Effect of renal replacement therapy on cellular cytokine production in patients with renal disease.Kidney Int1990; 38: 129–35.
28.
PertosaG., MarfellaC., TarantinoE.A.Involvement of peripheral blood monocytes in hemodialysis: in vivo induction of tumor necrosis factor alpha, interleukin 6 and beta2-macroglobulin.Nephrol Dial Transplant1991; 6(Suppl 2): 18–23.
29.
HerbelinA., UrenaP., NguyenA.T., ZingraffJ., Descamps LatschaB.Influence of first and long-term dialysis on uremia-associated increased basal production of interleukin-l and tumor necrosis factor by circulating monocytes.Nephrol Dial Transplant1991; 6: 349–57.
30.
HerbelinA., UrenaP., NguyenA.T., ZingraffJ., Descamps LatschaB.Elevated circulating levels of interleukin-6 in patients with chronic renal failure.Kidney Int1991; 39: 954–60.
31.
MemoliB., LibettaC., RampinnoT.Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells.Kidney Int1992; 42: 320–6.
32.
GirndtM., KohlerH., Schiedhelm-WeickE., SchlaakJ.F., MeyerzumBuscheenfelde K-H, FleischerB.Production of interleukin-6, tumor necrosis factor and interleukin 10 in vitro corrrelates with the clinical immune defect in chronic hemodialysis patients.Kidney Int1995; 47: 559–65.
33.
LamarJ.M., AdamsJ., Carman-ArabV., BakeA., SakiR., JordanC.1,25-Dihydroxy vitamin-D3 suppresses human helper/inductor lymphocyte activity in vitro.J Immunol1985; 34: 2032–5.
34.
RigbyW.F.C., DenomeS., FangerM.W.Regulation of Iymphokine production and human T lymphocyte activation by 1,25-Dihydroxyvitamin D3.J ClinInvest1987; 79: 1659.
35.
35. ThickestC.D., WartyD., EscobarS.S., ProvvediniD.M., DinarelloC.A., HystmyerF.G., ManolagasS.C.Inhibition of interleukin-l production by 1,25-dihydroxy vitamin D3.J Clin Endocrinol Metab1989; 69: 127–33.
36.
HaynesR.D.A drenocorticotrophic hormone; adrenocortical steroids and their synthetic analogues; inhibitors of adrenocortical steroid biosynthesis. In: GilmanA.G., RallT.W., NiesA.S., TaylorP., eds. Goodman and Gilman's The pharmacologic basis of therapeutics. 8th Ed. Chap 60.New York: Permagon, 1990: 1431–62.
37.
LanghoffE., LadefogedJ.Relative immunosuppressive potency of various corticosteroids measured in vitro.Eur J Clin Pharmacol1983; 25: 459–62.
38.
LanghoffE., LadefogedJ., DickmeissE.E.The immunosuppressive potency of various steroids on peripheral blood lymphocytes, T cells, NK and K cells.Int J Immunopharmacol1985; 7: 483–9.
39.
LanghoffE., OlgaardK., LadefogedJ.The immunosuppressive potency in vitro of physiological and synthetic steroids on lymphocyte cultures.Int J Immunopharmacol1987; 9: 469–73.
